GPT and metabolic dysfunction-associated steatotic liver disease: Finally, through in vivo experiments, it was found that PET and core active compound 3 treatment significantly alleviated liver steatosis and reduced the levels of AST, ALT, TG and total cholesterol (TC) in mice, and finally confirmed its significant regulatory effect on NAFLD.